We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technique May Lead to Rejection-Free Adult Stem Cells

By LabMedica International staff writers
Posted on 14 Aug 2012
Patient-specific, blood-producing stem cells could soon be generated in the laboratory, eliminating the need for harvesting bone marrow--or finding a matching donor--for patients needing a bone marrow transplant. More...
German scientists have generated blood-forming stem cells from pluripotent stem cells in the laboratory without using animal serum, a technique that could lead to the production of rejection-free adult stem cells.

Researchers Dr. Bernhard Schiedlmeier and Hannes Klump led the study, which was published August 6, 2012, in the journal STEM CELLS Translational Medicine.

The scientists used mouse embryonic stem cells to grow blood-forming stem cells in low-oxygen conditions in the lab without using any serum or supportive cells known as stroma. When they transplanted the blood-forming cells into mice, they found the cells were capable of rebuilding the mice’s blood-forming system.

This findings means that scientists may ultimately be able to create blood stem cells from transplant patients in a laboratory instead of than using stem cells from unrelated donors, avoiding hazardous graft versus host reactions. “If our protocol can be adapted to humans and combined with induced pluripotent stem cell technology, it will open the door to producing adult stem cells that a patient’s body should not reject,” Dr. Klump said.

“These researchers have made progress toward the idea of one day using a patient’s own skin cells, or other cell types, to make blood-producing cells in the laboratory,” said Anthony Atala, MD, editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC, USA). “These findings are important for the translational aspects of using iPS cells.”

Dr. Schiedlmeier works in the department of experimental biology at Hannover Medical School (Germany) and Dr. Klump works at the Institute for Transfusion Medicine at University Hospital Essen (Germany).

Related Links:

Hannover Medical School
University Hospital Essen




Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.